The US FDA’s Neurology Products Division is taking a lead role in the first wave of externally organized patient input meetings as the agency transitions to a new model to succeed the first wave of FDA-organized and hosted events.
There have been four official meetings under the external model so far, as tracked by FDA based on meetings convened...